在阿尔茨海默氏病中,APOE ε4 影响了功能连接的动态变化和认知表现
ChengBing Gong1, WenTing Song1, ZhengYang Zhu2
1Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Journal of Alzheimer's disease : JAD
|March 28, 2025
概括
APOE ε4基因变异通过改变小脑的动态功能连接及其与叶的连接,使阿尔茨海默病的认知衰退恶化.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学是一种遗传学.
- 阿尔茨海默氏症疾病研究研究
背景情况:
- Apolipoprotein E (APOE) ε4 是阿尔茨海默病 (AD) 的一个主要遗传风险因素.
- APOE ε4对AD的动态功能连接 (dFC) 的影响仍未得到充分研究.
- 了解dFC变化对于阐明AD病理生理学至关重要.
研究的目的:
- 为了研究APOE ε4对AD患者dFC变异性的影响.
- 检查AD中dFC和认知表现之间的关系.
- 确定dFC是否调解APOE ε4和认知衰退之间的关联.
主要方法:
- 分析了AD患者的dFC,使用低频波动的动态分数幅度 (dfALFF) 和动态区域均性 (dReHo).
- 将APOE ε4载体 (n=33) 与非载体 (n=41) 进行比较.
- 使用相关性和调解分析将dFC,APOE ε4状态和认知联系起来.
主要成果:
- 携带APOE ε4的患者表现出更严重的认知障碍,以及脑小叶后部dReHo/dfALFF的减少.
- 在携带者中观察到左后大脑叶和左中圈之间较低的dFC.
- 这种减少的dFC与执行功能和处理速度有积极的相关性;调解分析证实其在执行功能障碍中的作用.
结论:
- 在AD患者中,APOE ε4显著调节小脑内的动态通信.
- APOE ε4影响小脑和叶之间的dFC,导致认知缺陷.
- 这些发现突显了改变dFC在APOE ε4相关的AD病变发生过程中的作用.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35